Theravance Biopharma Announces Initiation of Phase 2b Study of Velusetrag (TD-5108) for the Treatment of Gastroparesis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. AWK
9. ACN
10. USO

Go back to Theravance Biopharma Announces Initiation of Phase 2b Study of Velusetrag (TD-5108) for the Treatment of Gastroparesis
(NASDAQ: TBPH) Delayed: 16.97 +0.41 (2.48%)
Previous Close $16.56    52 Week High $38.92 
Open $16.70    52 Week Low $12.87 
Day High $17.10    P/E N/A 
Day Low $16.64    EPS $0.00 
Volume 676,267